Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) Moat Score: 0/10 (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603392 Beijing Wantai Biological Pharmacy Enterprise Co Ltd SHSE:603392
53 GF Score
Price ¥29.45
GF Value ¥42.07
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Beijing Wantai Biological Pharmacy Enterprise Co Moat Score?

Beijing Wantai Biological Pharmacy Enterprise Co has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Beijing Wantai Biological Pharmacy Enterprise Co has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Beijing Wantai Biological Pharmacy Enterprise Co might have No Moat - No discernible moat.

Beijing Wantai Biological Pharmacy Enterprise Co  (SHSE:603392) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Beijing Wantai Biological Pharmacy Enterprise Co Moat Score Related Terms

SHSE:603392
53GF Score
Beijing Wantai Biological Pharmacy Enterprise Co Ltd SHSE:603392
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) Overvalued in 2026?

Based on GuruFocus' analysis, Beijing Wantai Biological Pharmacy Enterprise Co stock appears to be undervalued. The current stock price of ¥29.45 is trading 30% below its estimated GF Value™ of ¥42.07. GuruFocus considers Beijing Wantai Biological Pharmacy Enterprise Co to be Possible Value Trap.

Key valuation signals for SHSE:603392:

  • Moat Score: 0
  • GF Value™: ¥42.07 vs. price of ¥29.45 (30% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603392 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beijing Wantai Biological Pharmacy Enterprise Co Business Description

Address No. 31, Science Park Road, Changping District, Beijing, CHN, 102206
Beijing Wantai Biological Pharmacy Enterprise Co Ltd is engaged in research, development, production, and sales of in vitro diagnostic reagents, instruments, and vaccines. The company has two segments: Diagnostic and Vaccine. The Diagnostic segment develops and sells in vitro diagnostic reagents such as ELISA, colloidal gold, biochemical, and chemiluminescent kits, along with instruments including chemiluminescent analyzers, fluorescent analyzers, and nucleic acid purification systems. The Vaccine segment focuses on products like the hepatitis E vaccine, the bivalent HPV vaccine, and the nasal spray COVID-19 vaccine. It generates the majority of its revenue from the Diagnostic segment.
53GF Score

Get the complete analysis for SHSE:603392

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥29.45
Price
¥42.07
GF Value